Olaparib may be sufficient for PSA recurrent prostate cancer among men with BRCA2 alterations
CANCER DIGEST – Aug. 24, 2024 – Men with mutations in a certain gene and whose prostate cancer is recurring as judged by a rising PSA,...
Confirmation of combination hormone blocking therapy approach for recurrent prostate cancer
CANCER DIGEST – Jan. 28, 2024 – A new multi-center study, led by Rahul Aggarwall, MD, a professor at UCSF School of Medicine, has shown...
Combination therapy for recurrent prostate cancer may slow progression and extend survival
CANCER DIGEST – Oct. 21, 2023 – Men with aggressive recurrent prostate cancer who were given a combination therapy aimed at hormone...
